Insmed Inc. (INSM)
Insmed (INSM) Reports Q4 Earnings: What Key Metrics Have to Say
The headline numbers for Insmed (INSM) give insight into how the company performed in the quarter ended December 2025, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Insmed (INSM) Reports Q4 Loss, Lags Revenue Estimates
Insmed (INSM) came out with a quarterly loss of $1.54 per share versus the Zacks Consensus Estimate of a loss of $1.07. This compares to a loss of $1.32 per share a year ago.
Insmed (INSM) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
Insmed (INSM) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Insmed: A Brensocatib Pipeline Setback Is Masking A Dupixent-Like Launch
Insmed remains a compelling buy after an ~30% pullback, as Brinsupri's blockbuster launch trajectory outpaces initial expectations. Brinsupri delivered $144.6M in Q4 sales and 11,550 patient starts in 2025, with only 4.6% TAM penetration, supporting robust future growth. Arikayce's ENCORE trial in March/April 2026 could expand its market from 30,000 to 200,000 patients, offering a major sales catalyst.
Insmed Incorporated (INSM) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Insmed Incorporated (INSM) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
INSM Stock Jumps on 2025 Preliminary Sales, 2026 Goals Announced
Shares of Insmed rise after it tops FY25 sales forecasts, led by strong Brinsupri uptake, and outlines 2026 guidance and pipeline milestones.
INSM Stock Up 78% in 6 Months: Here's What You Need to Know
Insmed shares surged on FDA and EU approvals of Brinsupri, strong uptake, and a growing pipeline which fueled optimism around its revenue outlook.
The Zacks Analyst Blog Mineralys, Lyell, Insmed and Nektar
Mineralys Therapeutics leads a biotech surge, with four drug stocks up over 50% in 2025 and catalysts lining up for more upside in 2026.
4 Drug, Biotech Stocks Rising More Than 50% in 2025 With Room to Grow
MLYS, LYEL, NKTR and INSM rise more than 50% in 2025 as clinical wins, FDA approvals and M&A deals revive sector momentum heading into 2026.
Mizuho's Jared Holz talks Insmed sinking double digits on sinus drug trial news
Mizuho's Jared Holz joins 'Fast Money' to talk Insmed shares tanking on discontinuing development of sinus drug.
INSM Stock Plummets on Sinus Study Failure, Adds New Pipeline Asset
Insmed sinks nearly 20% after Brinsupri failed a phase IIb sinus study, while the company adds a new monoclonal antibody asset to expand its pipeline.
Billionaire Stanley Druckenmiller is Betting $1.2 Billion in These 3 Stocks
Stanley Druckenmiller is a Wall Street legend whose trades are truly worth tracking due to how consistently he has been winning.
